HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)

10.1158/1538-7445.sabcs15-ot3-01-01 ◽

2016 ◽

Author(s):

K Miller ◽

J Cortes ◽

SA Hurvitz ◽

IE Krop ◽

D Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps641 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS641-TPS641 ◽

Cited By ~ 2

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A. Hurvitz ◽

Ian E. Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1

Annals of Oncology ◽

10.1093/annonc/mdw365.94 ◽

2016 ◽

Vol 27 ◽

pp. vi99

Author(s):

J. Cortes Castan ◽

S. Verma ◽

S. Hurvitz ◽

I.E. Krop ◽

D. Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe

10.1158/1538-7445.sabcs14-ot3-1-10 ◽

2015 ◽

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A Hurvitz ◽

Ian E Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

10.1158/1538-7445.sabcs20-pd3-11 ◽

2021 ◽

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Taira Naruto ◽

Norikazu Masuda ◽

Masato Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps636 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS636-TPS636

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Masahiro Kashiwaba ◽

Naruto Taira ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab PLUS Capecitabine and Capecitabine ALONE in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.241 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Cost Utility ◽

Trastuzumab Emtansine ◽

Utility Model ◽

Her2 Positive ◽

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/ajco.12292 ◽

2014 ◽

Vol 10 (4) ◽

pp. 368-375 ◽

Cited By ~ 3

Author(s):

Arlene Chan ◽

Catherine Shannon ◽

Richard de Boer ◽

Sally Baron-Hay ◽

Andrew Redfern ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3288216 ◽

2018 ◽

Author(s):

Fei Ma ◽

Quchang Ouyang ◽

Binghe Xu ◽

Wei Li ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽